Blocking ANGPTL4 to help people with severe community-acquired pneumonia
Targeting Angiopoietin-like 4 (ANGPTL4) in Severe Community Acquired Pneumonia
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11312617
This project will test whether blocking the blood protein ANGPTL4 helps adults hospitalized with severe community-acquired pneumonia recover faster and survive more often.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11312617 on ClinicalTrials.gov |
What this research studies
If you join, researchers will measure ANGPTL4 levels in your blood and link those levels to outcomes like ventilator-free days and survival. The team will use data from a large multi-center patient cohort and analyze thousands of plasma proteins to find patterns related to worse outcomes. They will also rely on animal experiments where genetic targeting or antibody blocking of ANGPTL4 reduced lung injury to guide possible treatments. If results look promising, the work could move toward testing monoclonal antibodies against ANGPTL4 in people.
Who could benefit from this research
Good fit: Adults hospitalized with severe community-acquired pneumonia (bacterial or viral), especially those in intensive care or needing respiratory support, would be the ideal candidates.
Not a fit: People with mild outpatient-treated pneumonia, conditions not related to ANGPTL4, or unrelated chronic illnesses are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: If successful, targeting ANGPTL4 could reduce organ failure, shorten time on ventilators, and improve survival for people with severe pneumonia.
How similar studies have performed: Observational human data link higher ANGPTL4 to worse outcomes and mouse studies plus preclinical monoclonal antibody work showed protection in viral pneumonia, but clinical testing of ANGPTL4-blocking therapies in people is still novel.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BHATRAJU, PAVAN KUMAR — UNIVERSITY OF WASHINGTON
- Study coordinator: BHATRAJU, PAVAN KUMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.